SURVIVAL OF THE FITTEST: CHALLENGING TRANSDUCED CELLS WITH HIV-1 REPLICATION
SURVIVAL OF THE FITTEST: CHALLENGING TRANSDUCED CELLS WITH HIV-1 REPLICATION
批准号:
7715531
负责人:
Stephen Edward Braun
金额:
$12.98万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-06-05 至 2009-04-30
关键词:
Cell LineCellsClinicalComputer Retrieval of Information on Scientific Projects DatabaseFundingGaggingGeneticGrantGreen Fluorescent ProteinsHIVHIV-1In VitroInfectionInstitutionLentivirus VectorPopulationRangeResearchResearch PersonnelResourcesSourceTranslationsUnited States National Institutes of HealthViralViruscellular transductiondaygene therapygenetic inhibitorgenetically modified cellsin vivoinhibitor/antagonistsmall hairpin RNAtherapeutic gene
中文摘要
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
各种遗传策略,包括shRNA或病毒进入抑制剂,已被证明在体外抑制HIV-1复制。将这些有效的体外策略转化为临床有效的治疗方法在很大程度上受到限制,这在很大程度上是因为体内可以实现的转基因细胞水平很低。然而,在临床情况下,治疗性基因的表达可能会保护转导细胞免受致病效应的影响,转导细胞可能具有选择性增殖优势,并重新填充细胞室。为了评估各种HIV基因治疗策略保护表达基因抑制物的细胞免受病毒诱导的细胞病变的可能性,并在体外提供选择性优势,将表达GFP的慢病毒载体与HIV-1 TAT/rev特异性小发夹(Sh)RNA或病毒进入抑制剂M87o一起转导到CD4+细胞系CEMx174。感染HIV-1后,CEMx174-M87o细胞中GFP+细胞的百分比从30%增加到95%以上,但在未感染细胞、感染的CEMx174-GFP细胞和CEMx174-sh(Tat/rev)细胞中GFP+细胞的百分比没有变化。为了评估选择性生长的下限,检测了HIV-1NL4-3感染后CEMx174-M87o和未转导细胞的混合细胞中的病毒复制和GFP表达。21天后,CEMx174-M87o混合物中GFP+细胞的百分率从1%上升到95%以上。在转导细胞中,HIV-1 p24 Gag的细胞内表达在第9天增加,但在第21天减弱。这些结果表明,病毒进入抑制剂M87o非常有效地抑制了HIV-1病毒的复制,重要的是,转导细胞在体外具有生存优势。
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
A variety of genetic strategies, including shRNA or viral entry inhibitors, have been documented to inhibit HIV-1 replication in vitro. Translation of these effective in vitro strategies to clinically efficacious treatments has been limited in large part due to the low levels of genetically modified cells that can be achieved in vivo. However, in clinical scenarios where expression of the therapeutic gene may protect transduced cell from pathogenic effects, the transduced cells may have a selective proliferative advantage and repopulate the cellular compartment. To assess the potential of various HIV gene therapy strategies to protect cells expressing genetic inhibitors from virus-induced cytopathicity and to provide for a selective advantage in vitro, the CD4+ cell line CEMx174 was transduced with lentiviral vectors expressing GFP along with either a HIV-1 tat/rev-specific small hairpin (sh)RNA or the viral entry inhibitor M87o. After infection with HIV-1, the percentage of GFP+ cells in the CEMx174-M87o population increased from 30% to greater than 95%, but was unchanged in uninfected cells, and in infected CEMx174-GFP cells and CEMx174-sh(tat/rev) cells. To assess the lower limit for selective outgrowth, viral replication and GFP expression were examined in mixtures of CEMx174-M87o and untransduced cells ranging from 1% to 100% following HIV-1 NL4-3 infection. After 21 days, the percentage of GFP+ cells in the CEMx174-M87o mixture increased from 1% to greater than 95%. Intracellular expression of HIV-1 p24 Gag increased in transduced cells through day 9, but then receded by day 21. These results demonstrate very potent inhibition of HIV-1 viral replication with the viral entry inhibitor M87o and, importantly, a survival advantage of transduced cells in vitro.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genetically Modified NKT Cells to Target Viral Reservoirs
-
批准号:9908047
-
项目类别:
-
资助金额:$17.0万
-
财政年份:2019
-
负责人:Stephen Edward Braun
-
依托单位:
Modified CMV-specific T cells to Target HIV
-
批准号:8930050
-
项目类别:
-
资助金额:$18.42万
-
财政年份:2014
-
负责人:Stephen Edward Braun
-
依托单位:
Modified CMV-specific T cells to Target HIV
-
批准号:8842407
-
项目类别:
-
资助金额:$19.85万
-
财政年份:2014
-
负责人:Stephen Edward Braun
-
依托单位:
Modified CMV-specific T cells to Target HIV
-
批准号:9177838
-
项目类别:
-
资助金额:$8.66万
-
财政年份:2014
-
负责人:Stephen Edward Braun
-
依托单位:
STEM CELL GENE THERAPY FOR AIDS USING AN ANTI-SIV ENVELOPE ANTISENSE MOLECULE
-
批准号:7715502
-
项目类别:
-
资助金额:$12.98万
-
财政年份:2008
-
负责人:Stephen Edward Braun
-
依托单位:
国内基金
海外基金
登录
查看更多内容
分化肌细胞脱细胞ECM-cells sheet 3D
支架构建及其促进容积性肌组织缺损再
生修复应用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:肖将尉
-
依托单位:
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
-
批准号:82072862
-
项目类别:面上项目
-
资助金额:56.0万元
-
批准年份:2020
-
负责人:徐云升
-
依托单位:
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
-
批准号:82070825
-
项目类别:面上项目
-
资助金额:53.0万元
-
批准年份:2020
-
负责人:徐西振
-
依托单位:
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
-
批准号:81903002
-
项目类别:青年科学基金项目
-
资助金额:20.5万元
-
批准年份:2019
-
负责人:王斐斐
-
依托单位:
HA/CD44在乳腺癌转移“先导细胞”(leader cells)侵袭中的作用及机制研究
-
批准号:81402419
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2014
-
负责人:杨翠霞
-
依托单位:
双模式编码的慢病毒载体转染C6 Glioma Cells的影像学研究
-
批准号:81271563
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2012
-
负责人:陈正光
-
依托单位:
树突状细胞(Dendritic cells,DCs)介导的黏膜免疫对猪轮状病毒(PRV)感染的分子作用机制研究
-
批准号:31272541
-
项目类别:面上项目
-
资助金额:82.0万元
-
批准年份:2012
-
负责人:王春凤
-
依托单位:
MTA2在睾丸支持细胞(Sertoli cells)中的功能和机制研究
-
批准号:31271248
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2012
-
负责人:李伟
-
依托单位:
无外源性基因iPS cells向肠细胞分化及对肠损伤的修复
-
批准号:81160050
-
项目类别:地区科学基金项目
-
资助金额:49.0万元
-
批准年份:2011
-
负责人:邵立健
-
依托单位: